Oncology Views & Analysis

Views & Analysis

ASCO 2019 Live coverage

ASCO 2019 day five

Exclusive live coverage from day five of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, prod

Videos

Kantar video image ASCO 2019 clinical practices

ASCO 2019 - Kantar highlights a selection of exciting Phase ...

At ASCO, a lot of attention is given to the results of the large, clinical practices changing phase III studies, but the future is also here. Early phase I and II trials that test

Videos

ASCO 2019 - Enfortumab comes out fighting in bladder cancer

At ASCO 2019, results were presented from the phase II EV-201 trial, which evaluated antibody drug conjugate (ADC) enfortumab vedotin in relapsed patients with locally advanced or metastati

ASCO 2019 and the future of oncology

ASCO 2019 - Kantar reviews results from phase 3 POLO trial

Lynparza is paving new ground in pancreatic cancer, aiming to establish a maintenance setting and patient segmentation based on a biomarker (gBRCA mt) in first-line metastatic disease.

ASCO 2019 Live coverage

ASCO 2019 day four

Exclusive live coverage from day four of the American Society of Clinical Oncology's annual meeting in Chicago. • To view all of our coverage from the preeminent cancer event, prod

ASCO 2019 and the future of oncology

ASCO 2019 - Kantar reviews multiple myeloma showdown

Day three of ASCO 2019 saw a showdown between two anti-CD38 compounds in multiple myeloma, Janssen's Darzalex and Sanofi's isatuximab. Darzalex showed more positive data in newly-d